GlycoVaxyn is a clinical stage biopharmaceutical company focused on the development and manufacture of next-generation bioconjugate vaccines utilizing its proprietary recombinant DNA technology.



 
11.09.14 GlycoVaxyn AG to Present at the 25th Joint Glycobiology Meeting in Gent, Belgium
07.08.14 GlycoVaxyn AG to Present at the 248th ACS National Meeting & Exposition in San Francisco, USA
01.07.14 GlycoVaxyn AG Announces the Inititation of a Phase I Clinical Trial in Collaboration with Janssen
 

GlycoVaxyn will be present during:

- Joint Meeting of the Society for Glycobiology in Honolulu on November 16-19, 2014

- 25th Joint Glycobiology Meeting in Gent on September 14-16, 2014

- The 6th Baltic Meeting on Microbial Carbohydrates in Gdansk on September 7-10, 2014